Pharmacology, Toxicology and Pharmaceutical Science
Rheumatoid Arthritis
100%
Inflammatory Arthritis
100%
Pulmonary Hypertension
74%
Remission
64%
Systemic Sclerosis
62%
Systemic Lupus Erythematosus
52%
Tocilizumab
35%
Pulmonary Veno-Occlusive Disease
33%
Rheumatic Disease
33%
Glucocorticoid
31%
Biological Marker
26%
Disease Activity
25%
Myocardial Disease
22%
Cohort Study
22%
Rituximab
22%
Prothrombin Antibody
22%
Methotrexate
22%
Connective Tissue Disease
22%
Pulmonary Capillary Hemangiomatosis
21%
Interstitial Lung Disease
19%
Clinical Feature
17%
Antiphospholipid Syndrome
16%
Microscopic Polyangiitis
16%
Wegener Granulomatosis
16%
Clinical Trial
15%
Vasculitis
15%
Thrombosis
14%
ANCA Associated Vasculitis
14%
Cyclophosphamide
14%
Immunosuppressive Agent
13%
Observational Study
12%
Antiphospholipid Antibody
12%
Peripheral Vasodilating Agent
12%
Mixed Connective Tissue Disease
12%
Diseases
11%
Phosphotransferase
11%
Enzyme Immunoassay
11%
Placebo
11%
Cartilage Degeneration
11%
Enteritis
11%
Abatacept
11%
Itaconic Acid
11%
Nintedanib
11%
Polycyclic Aromatic Hydrocarbon
11%
Janus Kinase Inhibitor
11%
Thrombocytopenia
11%
Phosphatidylserine
11%
Amyloid A Protein
11%
Enzyme-Linked Immunosorbent Assay
11%
Vitamin D
11%
Medicine and Dentistry
Pulmonary Hypertension
84%
Inflammatory Arthritis
57%
Rheumatoid Arthritis
57%
Systemic Lupus Erythematosus
52%
Connective Tissue Disease
37%
Systemic Scleroderma
33%
Cardiac Magnetic Resonance Imaging
30%
Antiphospholipid Syndrome
27%
Immunosuppressive Treatment
26%
Finger Joint
26%
Lupus Erythematosus
26%
Clinical Feature
25%
Biological Marker
23%
Rheumatic Disease
23%
Lupus Nephritis
22%
Glucocorticoid
20%
Thrombosis
19%
ANCA Associated Vasculitis
15%
Antiphospholipid Antibody
15%
Cyclophosphamide
14%
Metacarpophalangeal Joint
13%
Disease Activity
13%
Polycyclic Aromatic Hydrocarbon
13%
Heart Disease
12%
Cohort Analysis
12%
Heart Failure with Preserved Ejection Fraction
11%
Platelet
11%
Prognostication
11%
Myocardial Disease
11%
Cancer
11%
Cartilage Degeneration
11%
Whole Body MRI
11%
Tumor Marker
11%
Granulomatosis with Polyangiitis
11%
Microscopic Polyangiitis
11%
Enteritis
11%
Nintedanib
11%
Mixed Connective Tissue Disease
11%
Catheterization
11%
Clinical Study
11%
Venous Thromboembolism
11%
Cluster Analysis
11%
Nicotinic Receptor
11%
Right Ventricular Function
11%
Interferon
11%
Posterior Reversible Encephalopathy Syndrome
11%
Hepatitis E Virus
11%
Pulmonary Capillary Hemangiomatosis
11%
Bone Destruction
11%
Risk Stratification
11%
Keyphrases
Japanese Patients
22%
4th Edition
22%
Systemic Sclerosis
22%
Autophagy
22%
Pulmonary Arterial Hypertension
16%
Clinical Features
13%
Systemic Lupus Erythematosus
13%
Cyclophosphamide
13%
Systemic Sclerosis-associated Pulmonary Arterial Hypertension
13%
Phase II Trial
11%
Destructive Arthritis
11%
RASGRP2
11%
Complement Components
11%
Pulmonary Arteritis
11%
Treatment Prediction
11%
Myofascia
11%
Remission
11%
Whole-body MRI
11%
Mx1 Protein
11%
Cardiomyopathy
11%
CalDAG-GEFI
11%
Power Doppler Signal
11%
Lupus Enteritis
11%
Ultrasonographic Features
11%
Signal Assessment
11%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
11%
MicroRNA-9
11%
MiR-9
11%
Partial Images
11%
Remission Induction
11%
Corticocortical
11%
Intermediary Factors
11%
Risedronate Sodium
11%
Phase Correlation
11%
Treatment-related
11%
I-domain
11%
Cardiac Magnetic Resonance
11%
Glycoprotein I
11%
Maintenance Safety
11%
Ribophorin II
11%
Posterior Reversible Encephalopathy Syndrome
11%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
11%
Disease-associated
11%
Reliability Study
11%
Rituximab
11%
Quantitative Chest CT
11%
Pulmonary Vasodilator Therapy
11%
CTD-PAH
11%
Occult Hepatitis B Virus Infection
11%
Mixed Connective Tissue Disease
11%
